

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-31. (Cancelled)

32. (Currently Amended) A liposomal formulation, said liposomal formulation comprising:

a) ~~an antineoplastic drug; and~~

b) ~~a liposome having free antineoplastic drug and precipitated antineoplastic drug, wherein the precipitated antineoplastic drug in said liposome is at least 50% of the total antineoplastic drug, wherein said liposome comprises sphingomyelin and cholesterol, and wherein said antineoplastic drug is a camptothecin.~~

33. (Cancelled)

34. (Previously Presented) The liposomal formulation of claim 32, wherein said camptothecin is a member selected from the group consisting of irinotecan, topotecan, 9-amino camptothecin, 10,11-methylenedioxy camptothecin, 9-nitro camptothecin, TAS 103, 7-(4-methyl-piperazino-methylene)-10, 11-ethylenedioxy-20(S)-camptothecin and 7-(2-N-isopropylamino)ethyl)-20(S)-camptothecin.

35. (Original) The liposomal formulation of claim 34, wherein said camptothecin is topotecan.

36. (Currently Amended) A liposomal formulation, said liposomal formulation comprising:

a) ~~an antineoplastic drug; and~~

b) — a liposome having free antineoplastic drug and precipitated antineoplastic drug, wherein the precipitated antineoplastic drug in said liposome is at least 50% of the total antineoplastic drug, wherein said liposome comprises sphingomyelin and cholesterol at a ratio in the range of about 75/25 mol%/mol% sphingomyelin/cholesterol to about 35/50 mol%/mol% sphingomyelin/cholesterol, and wherein said antineoplastic drug is a vinca alkaloid.

37. (Cancelled)

38. (Original) The liposomal formulation of claim 36, wherein said vinca alkaloid is a member selected from the group consisting of vincristine, vinblastine, vinorelbine and vindesine.

39. (Original) The liposomal formulation of claim 32, wherein the ratio of said antineoplastic drug to lipid is about 0.005-1:1 (w/w).

40. (Original) The liposomal formulation of claim 39, wherein the ratio of said antineoplastic drug: said lipid is about 0.05-0.9:1 (w/w).

41. (Original) The liposomal formulation of claim 40, wherein the ratio of said antineoplastic drug: said lipid is about 0.1-0.5:1 (w/w).

42. (Cancelled)

43. (Previously Presented) The liposomal formulation of claim 32 or 36, wherein said liposome comprises sphingomyelin and cholesterol in a 55:45 molar ratio.

44. (Currently Amended) The liposomal formulation of claim 32 or 36, further comprising a liposome with no encapsulated active agent.

45. (Withdrawn) The liposomal formulation of claim 44, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:0.5 to 1:1000.

46. (Withdrawn) The liposomal formulation of claim 45, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:1 to 1:100.

47. (Withdrawn) The liposomal formulation of claim 46, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:2 to 1:10.

48. (Withdrawn) The liposomal formulation of claim 47, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:3 to 1:5.

49.-63. (Cancelled)

64. (Previously Presented) The liposomal formulation of claim 36, wherein the ratio of said antineoplastic drug to lipid is about 0.005-1:1 (w/w).

65. (Previously Presented) The liposomal formulation of claim 64, wherein the ratio of said antineoplastic drug to said lipid is about 0.05-0.9:1 (w/w).

66. (Previously Presented) The liposomal formulation of claim 65, wherein the ratio of said antineoplastic drug to said lipid is about 0.1-0.5:1 (w/w).

67. (Previously Presented) The liposomal formulation of claim 32 or 36, wherein said liposome comprises sphingomyelin and cholesterol in a 50:50 molar ratio.